Spots Global Cancer Trial Database for cll
Every month we try and update this database with for cll cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | NCT00947388 | Recurrent Small... Refractory Chro... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Bendamustine Hy... Alemtuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | NCT02243124 | Myelodysplastic... | cenersen Dexamethasone | 18 Years - 95 Years | Eleos, Inc. | |
| Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | NCT02315768 | Chronic Lymphoc... | GA101 ibrutinib | 65 Years - | University of California, San Diego | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Oral Valganciclovir Versus Valacyclovir | NCT00562770 | Chronic Lymphoc... Leukemia | Valganciclovir Valacyclovir | 16 Years - | M.D. Anderson Cancer Center | |
| The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 | NCT04746092 | CLL Multiple Myelom... Lymphoma | 18 Years - 100 Years | Tel-Aviv Sourasky Medical Center | ||
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL | NCT02973399 | Cancer | SNX-5422 plus i... | 18 Years - | Esanex Inc. | |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia | NCT04964908 | Chronic Lymphoc... | 18 Years - | AstraZeneca | ||
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | NCT04608318 | Chronic Lymphoi... | Ibrutinib Venetoclax Obinutuzumab | 18 Years - | German CLL Study Group | |
| Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine | NCT01392079 | Chronic Lymphoc... | Alemtuzumab | 18 Years - | University of Ulm | |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT06428019 | Chronic Lymphoc... | Venetoclax Acalabrutinib Obinutuzumab | 18 Years - | AbbVie | |
| A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01539512 | Chronic Lymphoc... | Idelalisib Rituximab Placebo to matc... | 18 Years - | Gilead Sciences | |
| Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | NCT01403246 | Chronic Lymphoc... | Lenalidomide; C... | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. | NCT06334835 | Acute Lymphobla... | lncRNA signatur... | 1 Year - 18 Years | IRCCS SYNLAB SDN | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Lenalidomide and Obinutuzumab for Previously Untreated CLL | NCT02371590 | Chronic Lymphoc... | Lenalidomide Obinutuzumab | 18 Years - | University of California, San Diego | |
| Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation | NCT00428233 | Chronic Lymphoc... | Leukemia cell h... | 18 Years - | Dana-Farber Cancer Institute | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | NCT01569295 | Chronic Lymphoc... | Idelalisib Rituximab Bendamustine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT01243190 | Chronic Lymphoc... | Ofatumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | NCT01585688 | Non-Hodgkin's L... Chronic Lymphoc... | hLL1-DOX (IMMU-... | 18 Years - | Gilead Sciences | |
| Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) | NCT01144260 | B-Cell Chronic ... | bafetinib | 18 Years - | CytRx | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan | NCT06362044 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | NCT01191749 | Leukemia | Alemtuzumab | - | M.D. Anderson Cancer Center | |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | NCT00405743 | Hematologic Mal... AML | CP-4055 CP-4055 | 18 Years - | Clavis Pharma | |
| Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | NCT00836043 | Chronic Lymphoc... | Alemtuzumab (Ma... | 18 Years - | Sanofi | |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | NCT01352312 | Chronic Lymphoc... B-Cell Non-Hodg... | Bendamustine Pentostatin Ofatumumab | 18 Years - | Thomas Jefferson University | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | NCT01723839 | Chronic Lymphoc... | Fludarabine, Cy... | 18 Years - | Hackensack Meridian Health | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | NCT02582879 | Chronic Lymphoc... | 18 Years - | Pharmacyclics LLC. | ||
| Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | NCT02044822 | B-cell Chronic ... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | NCT05197192 | Chronic Lymphoc... | Obinutuzumab Venetoclax Acalabrutinib | 18 Years - 120 Years | German CLL Study Group | |
| Acalabrutinib Real World Italian obSErvational Study -ARISE | NCT06205498 | Chronic Lymphoc... | acalabrutinib | 18 Years - | AstraZeneca | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT00073489 | Chronic Lymphoc... | OSI-461 | 18 Years - | Astellas Pharma Inc | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | NCT00073489 | Chronic Lymphoc... | OSI-461 | 18 Years - | Astellas Pharma Inc | |
| A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT02801578 | Chronic Lymphoc... | Ibrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | NCT04515238 | Chronic Lymphoi... | Bendamustine Obinutuzumab Zanubrutinib Venetoclax | 18 Years - | German CLL Study Group | |
| Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia | NCT01460238 | Chronic Lymphoc... | 18 Years - | Dartmouth-Hitchcock Medical Center | ||
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | NCT00499239 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | GS-9219 | 18 Years - | Gilead Sciences | |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | NCT01161511 | Chronic Lymphoc... Small Lymphocyt... | XmAb5574 | 18 Years - | Xencor, Inc. | |
| A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | NCT01659047 | Chronic Lymphoc... | GS-1101 | 18 Years - | Gilead Sciences | |
| A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00496132 | Chronic Lymphoc... | PRO131921 | 18 Years - | Genentech, Inc. | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00328198 | B-Cell Chronic ... | Alemtuzumab Alemtuzumab | 18 Years - | Sanofi | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | NCT03588598 | Chronic Lymphoc... Small Lymphocyt... B-Cell Non-Hodg... | SHC014748M | 18 Years - 75 Years | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | NCT00924326 | Primary Mediast... Diffuse, Large ... Diffuse Large B... Mantle Cell | Fludarabine Cyclophosphamid... Anti-cluster of... Aldesleukin Fludarabine Cyclophosphamid... | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Stem Cell Transplantation for Patients With Cancers of the Blood | NCT00467961 | CML (Chronic My... CLL (Chronic Ly... AML (Acute Myel... Acute Lymphocyt... MDS (Myelodyspl... | Miltenyi system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00923182 | Leukemia, Lymph... | alemtuzumab | 20 Years - 75 Years | Sanofi | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT01976520 | Chronic Lymphoc... | Oncoquest-CLL v... | 18 Years - | XEME Biopharma Inc. | |
| Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | NCT01253460 | Leukemia | Cyclophosphamid... Rituximab Sapacitabine | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | NCT01723839 | Chronic Lymphoc... | Fludarabine, Cy... | 18 Years - | Hackensack Meridian Health | |
| A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia | NCT04016636 | CLL | Standard of Car... | 18 Years - | Fundaleu | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | NCT01728207 | Non-hodgkin's L... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... | IMMU-114 | 18 Years - | Gilead Sciences | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL | NCT04862806 | Chronic Lymphoc... | COVID-19 serolo... | 18 Years - | Bnai Zion Medical Center | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | NCT04240704 | Non-Hodgkins Ly... Chronic Lymphoc... | JBH492 | 18 Years - | Novartis | |
| Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia | NCT00962715 | Chronic Lymphoc... | Influenza Vacci... Pegylated inter... Interferon (IFN... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT06291220 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab ABBV-453 | 18 Years - | AbbVie | |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT06073821 | CLL | Sonrotoclax Zanubrutinib Venetoclax Obinutuzumab | 18 Years - | BeiGene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
